News & Events about Aerovate Therapeutics Inc.
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) CEO Timothy P. Noyes sold 15,000 shares of Aerovate Therapeutics stock in a transaction on Wednesday, February 1st. The stock was sold at an average price of $22.68, for a total transaction of $340,200.00. The sale was disclosed in a legal filing ...
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as ...
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) insider Benjamin T. Dake sold 10,284 shares of the businesss stock in a transaction that occurred on Friday, January 6th. The stock was sold at an average price of $25.98, for a total value of $267,178.32. Following the completion ...
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) insider Benjamin T. Dake sold 10,284 shares of the businesss stock in a transaction that occurred on Friday, January 6th. The stock was sold at an average price of $25.98, for a total value of $267,178.32. Following the completion of the ...
Ticker Report
5 months ago
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) was the target of a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 1,540,000 shares, an increase of 10.0% from the July 31st total of 1,400,000 shares. Based on an average...